English
Regional settings| Spread | 0.50 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ CHF 5,000.00 Short position overnight fee ~ CHF 4,000.00 | -0.014959% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ CHF 5,000.00 Short position overnight fee ~ CHF 4,000.00 | -0.007263% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | CHF | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Switzerland | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 40.25 |
| Open | 40.15 |
| 1-Year Change | -7.91% |
| Day's Range | 40.15 - 40.45 |
Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).
